Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Asset Writedowns and Impairment (2018 - 2024)

Historic Asset Writedowns and Impairment for Organogenesis Holdings (ORGO) over the last 6 years, with Q2 2024 value amounting to $18.8 million.

  • Organogenesis Holdings' Asset Writedowns and Impairment changed N/A to $18.8 million in Q2 2024 from the same period last year, while for Dec 2024 it was $18.8 million, marking a year-over-year increase of 1554426.23%. This contributed to the annual value of $18.8 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q2 2024, Organogenesis Holdings' Asset Writedowns and Impairment is $18.8 million.
  • Over the past 5 years, Organogenesis Holdings' Asset Writedowns and Impairment peaked at $18.8 million during Q2 2024, and registered a low of -$1.4 million during Q4 2020.
  • In the last 4 years, Organogenesis Holdings' Asset Writedowns and Impairment had a median value of $632000.0 in 2021 and averaged $1.8 million.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first soared by 293750.0% in 2020, then tumbled by 23528.48% in 2022.
  • Quarter analysis of 4 years shows Organogenesis Holdings' Asset Writedowns and Impairment stood at -$1.4 million in 2020, then soared by 145.93% to $632000.0 in 2021, then plummeted by 235.28% to -$855000.0 in 2022, then soared by 2303.74% to $18.8 million in 2024.
  • Its last three reported values are $18.8 million in Q2 2024, -$855000.0 for Q4 2022, and $733000.0 during Q3 2022.